Article
Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.
International journal of cancer - 20 Mar 2002
Jäger Elke, Höhn Hauni, Necker Artje, Förster Reinhold, Karbach Julia, Freitag Kirsten, Neukirch Claudia, Castelli Chiara, Salter Russell D, Knuth Alaxander, Maeurer Markus J
Abstract excerpt
Monitoring of CD8+ T-cell responses in cancer patients during peptide vaccination is essential to provide useful surrogate markers and to demonstrate vaccine efficacy. We have longitudinally followed CD8+ T-cell responses in 3 melanoma patients who were immunized with peptides derived from Melan-A/MART-1. Recombinant HLA-A2 tetramers loaded with the naturally presented Melan-A/MART-1 nonamer peptide (AAGIGILTV)...
Topics
- ATP-Binding Cassette Transporters
- Antibodies, Monoclonal
- Antigens, Neoplasm
- CD8-Positive T-Lymphocytes
- Cancer Vaccines
- Complementarity Determining Regions
- Flow Cytometry
- HLA-A2 Antigen
- Humans
- MART-1 Antigen
- Melanoma
- Neoplasm Proteins